Pharmaceutical

FDA accepts BeiGene’s sNDA for follicular lymphoma therapy

The US FDA has accepted for review BeiGene’s sNDA for Brukinsa plus obinutuzumab to treat follicular lymphoma.

Jul 13, 2023 - 20:00
FDA accepts BeiGene’s sNDA for follicular lymphoma therapy
The US FDA has accepted for review BeiGene’s sNDA for Brukinsa plus obinutuzumab to treat follicular lymphoma.
Read the original article

Tags:

Previous Article

Tenpoint raises funds to develop cell therapies for vision loss

Next Article

ICR to enter AI-powered cancer drug discovery partnership

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

New England Journal of Medicine reckons with its racist past and complicity in slavery

New England Journal of Medicine reckons with its racist...

Dec 7, 2023

After loved ones’ long-awaited organ transplants, caregivers often find challenges are just beginning

After loved ones’ long-awaited organ transplants, careg...

Jan 4, 2024

AbCellera and Regeneron expand antibody discovery collaboration

AbCellera and Regeneron expand antibody discovery colla...

Sep 21, 2023